Published on 9 Aug 2022 on Zacks via Yahoo Finance
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
Epizyme (EPZM) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.63 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 41.67%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.35 per share when it actually produced a loss of $0.39, delivering a surprise of -11.43%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.